Monte Rosa Therapeutics Q4 EPS $(0.58) Misses $(0.33) Estimate; Cash Balance Of $237M Is Expected To Provide Cash Runway Into First Half Of 2026
Monte Rosa Therapeutics Q4 EPS $(0.58) Misses $(0.33) Estimate; Cash Balance Of $237M Is Expected To Provide Cash Runway Into First Half Of 2026
Monte Rosa Therapeutics第四季度每股收益美元（0.58美元）未達到預期（0.33美元）；預計2.37億美元的現金餘額將爲2026年上半年提供現金流
Monte Rosa Therapeutics (NASDAQ:GLUE) reported quarterly losses of $(0.58) per share which missed the analyst consensus estimate of $(0.33) by 75.76 percent. This is a 7.94 percent increase over losses of $(0.63) per share from the same period last year.
Monte Rosa Therapeutics（納斯達克股票代碼：GLUE）公佈的季度虧損爲每股0.58美元，比分析師共識估計的0.33美元（0.33美元）低75.76％。與去年同期每股虧損0.63美元（0.63美元）相比，增長了7.94％。